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ABSTRACT
Objective: This study developed a sensitive, selective, and valid method for analyzing clopidogrel in human plasma using liquid chromatography-
tandem mass spectrometry (LC-MS/MS).
Methods: The chromatography separation was performed on the waters ACQUITY UPLC Class BEH C18 1.7 µm (2.1 × 100 mm) column, consisting of 
0.1% formic acid in water and 0.1% formic acid in acetonitrile (30-70) as the mobile phase, and an isocratic elution with a flow rate of 0.2 mL/minutes. 
The mass detection was performed using a Waters Xevo TQD equipped with positive electrospray ionization in the multiple reaction monitoring 
modes. The clopidogrel was detected at m/z 322.086>212.097 and irbesartan as an internal standard at m/z 429.233>207.131. The sample was 
prepared with protein precipitation method using acetonitrile, vortex mixed for 10 minutes, and centrifuged at 13,000 rpm for 20 minutes.
Results: This method showed a linear result at the concentration range of 0.2-10 ng/ml with r≥0.9997.
Conclusions: The developed method provides sensitivity, linearity, precision, and accuracy and is suitable for analysis of clopidogrel in human plasma 
using LC-MS/MS.
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INTRODUCTION
Clopidogrel is used for the secondary prevention of cerebral or 
myocardial infarction in patients who cannot tolerate acetylsalicylic 
acid or those who undergo a cerebral or myocardial infarction while 
taking acetylsalicylic acid [1]. The United States Food and Drug 
Administration has approved the drug to reduce the stroke level and 
the chance of myocardial infarction. Clopidogrel is a prodrug, with a 
slow onset, that has been found to be as effective as acetylsalicylic acid 
for secondary prevention in stroke. It provides a better toxicity profile, 
with a lower risk of causing thrombocytopenia and leucopenia, than 
other antiplatelet drugs, such as ticlopidine [2].
Clopidogrel is a platelet aggregation inhibitor that is systemically 
hydrolyzed into its inactive metabolite, carboxylic acid. The main 
clopidogrel concentration, or that which cannot be metabolized, has 
been found to be 2,000 times lower than the carboxylate acid metabolite. 
In addition, clopidogrel is metabolized into thiol, which is an active 
metabolite. The unstable chemical structure and low concentration 
are challenges in the analysis of clopidogrel in plasma [3-5]. Therefore, 
there is a need for a sensitive and selective method to measure the 
clopidogrel concentration in plasma, using liquid chromatography-
tandem mass spectrometry (LC-MS/MS).
In 2008, the guideline on the investigation of bioequivalence from 
the European Medicines Agency (EMA) stated that the measurement 
of the clopidogrel concentration in the plasma can be performed 
by measuring the inactive metabolite [6]. However, in 2010, it 
was suggested that a more accurate pharmacokinetic profile can 
be obtained by measuring the parent compound, not the inactive 
metabolite [7]. It was also suggested that special treatment was 
needed to prevent the conversion of the metabolite back into the 
parent drug (clopidogrel). This requires the use of low temperatures 
in the storage and extraction and refraining from the use of methanol 
during the analysis. This back-conversion could potentially occur 
when methanol is used as part of the extraction solvent, reconstitution 
solvent, chromatography mobile phase, or for the preparation of the 
calibrators, quality control (QC) solutions, and internal standards 
during the bioanalysis [3].
In 2007, a validation of the clopidogrel analytical method with liquid-
liquid extraction using diethyl ether was performed [8]. The lower limit 
of quantification (LLOQ) obtained in this study was 10 pg/mL, with a 
maximum serum concentration (Cmax) of 1.7 ng/ml, but this LLOQ still 
met the EMA recommendation, because it did not exceed a Cmax of 5%. 
However, this study used methanol to produce the stock solution and 
dilution; therefore, it was possible that back-conversion occurred, 
biasing the results. In 2012, another study conducted a validation of 
the clopidogrel analytical method through protein precipitation, which 
was simpler and did not use methanol in the analysis [8]. However, the 
LLOQ obtained in that study was 250 pg/ml, which was higher than the 
recommended limit.
In the current study, we performed an optimization of the plasma 
clopidogrel analysis method by modifying the published analysis 
method. The optimization performed was to change the internal 
standard to irbesartan and compare the results of the different 
sample preparation methods (liquid-liquid extraction and protein 
precipitation). Moreover, this study did not use methanol in the analysis 
to minimize bias in the clopidogrel concentration measurement results 
from the sample. The modified method was used to create a higher 
sensitivity and more valid result.
METHODS
Instrumentation
The ultrahigh-performance liquid chromatography (UHPLC)-MS/
MS (Xevo triple quadrupole (TQD) MS; Waters Corporation, Milford, 
Massachusetts, USA) consisted of a quaternary solvent manager 
(ACQUITY UPLC H-Class System; Waters Corporation, Milford, 
Massachusetts, USA), sample manager (ACQUITY UPLC H-Class System; 
Waters Corporation, Milford, Massachusetts, USA), nitrogen generator 
compressor (Peak Scientific, Milford, Massachusetts, USA), 2.1 mm 
× 100 mm C18-bonded silica column (1.7 µm ACQUITY UPLC BEH; 
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Waters Corporation, Milford, Massachusetts, USA), mass analyzer (Xevo 
TQD Mass Spectrometer; Waters Corporation, Milford, Massachusetts, 
USA) with an ionization source (Z-Spray; Milford, Massachusetts, USA), 
data analyzer software (MassLynx Software; Milford, Massachusetts, 
USA), and computer (Lenovo, Beijing, China).
Chemicals
The clopidogrel hydrogen sulfate (99.7%) was obtained from MSN 
Laboratories (Telangana, India), the irbesartan was obtained from the 
Zhejiang Huahai Pharmaceutical Co., Ltd., (Zhejiang, China), and the 
HPLC grade acetonitrile and formic acid were obtained from Merck 
(Darmstadt, Germany). All of the water used in this experiment was 
HPLC grade, prepared using a direct-Q 5 Water Purification System 
(Millipore, Watford, UK), and filtrated using 0.45 µm membrane 
filters (Sartorius UK Ltd., Epsom, UK). The plasma was obtained from 
Indonesian Blood Transfusion Service and stored at −20°C until use.
LC-MS/MS method
The chromatography consisted of an ACQUITY UPLC C18 column 
(1.7 μm, 100 × 2.1 mm; Waters Corporation, Milford, Massachusetts, 
USA), using the isocratic elution method with 0.1% formic acid in 
water and 0.1% formic acid in acetonitrile (30:70) as the mobile phase, 
a flow rate of 0.2 ml/minutes, and a column temperature of 35°C. 
The mass detection was performed using the electrospray ionization 
positive mode of the multiple reaction monitoring types, with an m/z 
(mass per charge ratio) value of 322.086>212.097 for the clopidogrel 
(Fig. 1) and 429.233>207.131 for the irbesartan (Fig. 2), and a run time 
of 5 minutes. The tandem mass spectrometer settings are detailed in 
Table 1.
Stock solutions, calibrators, and control solutions
The clopidogrel stock solutions were prepared by dissolving an 
appropriate amount of clopidogrel hydrogen sulfate in acetonitrile to 
give a final free base concentration of 0.1 mg/ml. The stock solutions 
were stored at −20°C until use. The calibrators and control solutions 
were prepared by spiking stock solutions in human plasma. The 
concentrations of the clopidogrel hydrogen sulfate used to make 
the calibration curves were 200, 500, 1000, 1500, 5000, 7500, and 
10,000 pg/ml. The concentrations of the QC samples were 7.5 ng/ml QC 
high, 5 ng/ml QC medium, and 1 ng/ml QC low QCL.
Preparation of the sample solution
Protein precipitation
A 250 μL of plasma containing clopidogrel with a concentration of 
100 ng/ml was put in a microtube, and then, 20 μL of irbesartan 
(100 ng/ml concentration) was added. This sample was vortex mixed 
for 30 seconds. Next, 750 μl of acetonitrile was added to precipitate 
the protein. This mixture was vortex mixed for 10 minutes and 
centrifuged for 20 minutes at 13,000 rpm. An aliquot from the 
centrifugation product was separated into other tube, and then, 
centrifuged again for 10 minutes at 3,000 rpm. The 300 μl aliquot 
obtained was separated into clean vials to be analyzed through the 
LC-MS/MS system.
Liquid-liquid extraction
A 250 μl of plasma containing clopidogrel with a concentration 
of 100 ng/ml was put in a microtube; then, 20 μl of irbesartan 
(100 ng/ml concentration) was added. This sample was vortex mixed 
for 30 seconds. The liquid-liquid extraction was performed by adding 
organic solvent equivalent to 8 times the amount of the total plasma. 
This mixture was then vortex mixed for 2 minutes and centrifuged 
at 3,000 rpm for 15 minutes. Next, 1.5 ml of the organic phase was 
moved to a test tube and evaporated until dry at 40°C using N2 gas for 
20 minutes. The residue obtained was reconstituted with 100 μl of 
the mobile phase (0.1% formic acid in water and 0.1% formic acid in 
acetonitrile, 50:50, v/v), then sonicated for 5 minutes, and vortex mixed 
for 1 minute. The reconstituted sample was moved into a microtube and 
centrifuged again for 10 minutes at 3,000 rpm. Then, 10 μl of aliquot 
was injected to the LC-MS/MS system. The organic solvents used in this 
method were ether and dichloromethane. The results obtained from 
the protein precipitation and liquid-liquid extractions were compared, 
the optimum extraction method was chosen, and the results were 
optimized again.
Method validation
After the optimization of the extraction sample, the validation of the 
analytical method was performed. The bioanalysis of the validation 
method parameters included the selectivity, carryover, LLOQ, linearity, 
accuracy and precision, recovery, dilution integrity, matrix effects, and 
stability. The analytical method validation was performed using control 
solutions and working solutions.
RESULTS AND DISCUSSION
Plasma preparation
The liquid-liquid extraction showed a higher response than the protein 
precipitation method although the contaminant area of the plasma 
blank was lower in the protein precipitation method. The results showed 
that the 200 pg/ml concentration in the liquid-liquid extraction using 
dichloromethane was 3,335 (as the analyte response), while the liquid-
liquid extraction using ether was 1,179, and the protein precipitation 
was 131. However, the protein precipitation method was used for the 
extraction in the final experiment because the liquid-liquid extraction 
required a longer time and produced a higher amount of contaminant, 
resulting in a more complicated validation method and a biased result. 
The analytical method using protein precipitation was found to be 
easier and faster and produced a lower amount of contamination. 
The protein precipitation method was then optimized. The optimum 
preparation method was found by adding 750 μl of acetonitrile to the 
plasma sample, then vortex mixing it for 10 minutes and stirring it with 
centrifugation for 20 minutes.
Fig. 1: Product ion mass spectra of clopidogrel
Fig. 2: Product ion mass spectra of irbesartan
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LLOQ measurement
According to the analysis performed by Karaźniewicz-Łada in 2012, the 
LLOQ obtained from the protein precipitation extraction method was 
250 pg/ml [8]. In this study, the concentration used to obtain the LLOQ 
was 200 pg/ml. The LLOQ obtained from the concentration of 200 pg/ml 
resulted in 14.8-18.57% as the relative error (%RE) values and 1.35% as the 
relative standard deviation (%RSD). According to the 2011 EMA Guideline 
on Bioanalytical Method Validation, the LLOQ value obtained should not 
exceed 5% of the Cmax value. The Cmax value of the 75 mg clopidogrel tablet 
was 2.1 ng/mL; therefore, the LLOQ should not exceed 105 pg/mL. This 
method did not meet the requirement; however, the LLOQ obtained was 
lower than that in the study by Karaźniewicz-Ładaz [9].
Calibration curve
The calibration curve ranged from 200 pg/ml to 10,000 pg/ml. The 
calibration curve included the plasma blank (plasma without analyte 
or internal standard), zero plasma (plasma with internal standard), 
and non-zero plasma (plasma with analyte and internal standard) at 7 
concentrations (200, 500, 1000, 1500, 5000, 7500, and 10,000 pg/ml). 
The calibration curve showed a linear regression using the following 
formula: y=0.0001+0.004x. The correlation value and %RE met the 
requirements of not more than ±15% for the concentration (without 
the LLOQ) and not more than ±20% for the LLOQ concentration. The 
average correlation coefficient was 0.9996.
Accuracy, precision, and recovery
The accuracy was performed to determine the proximity of the 
measurement result to the true amount of clopidogrel, which was 
expressed through the %RE. The precision was tested to determine 
the repeatability of the result obtained in this analysis, which was 
expressed through the %RSD. The %RE values obtained from the 
intraday accuracy test for the LLOQ concentration were 14.81-18.58%, 
and they were −13.65-9.24% from the other concentrations. For the 
intraday precision, the %RSD value obtained was 1.36% for the LLOQ, 
3.92% for the low concentration, 9.69% for the medium concentration, 
and 5.94% for the high concentration. For the interday accuracy test for 
the clopidogrel, the %RE values obtained for the LLOQ concentration 
were −14.00-18.58%, and they were −13.65-9.24% for the other 
concentrations. For the interday precision test, the %RSD value 
obtained was 10.72% for the LLOQ, 7.07 for the low concentration, 
7.09% for the medium concentration, and 4.42% for the high 
concentration. These results showed that the analytical method used 
met the requirements for intra- and inter-day accuracy and precision 
(Table 2). The recovery test for this analytical method was performed 
relatively, with the use of low, medium, and high concentrations. The 
relative recovery values obtained from the clopidogrel in the low, 
medium, and high concentrations were 86.48-102.95%, 86.25-103.6%, 
and 93.6-102.55%, respectively.
Table 1: Mass spectrometer settings for the analytical method
Compound Fragmentation ion (m/z) Capillary voltage (kV) Desolvation temperature (°C) Cone (V) Collision (V)
Clopidogrel 322.086>212.097 3.5 800 36 26
Irbesartan 429.233>207.131 38 24
Table 2: Intra- and inter-day precision and accuracy
Concentration (pg/mL) Day 1 Day 2 Day 3
Measured 
value (pg/mL)
%RE %RSD Measured 
value (pg/mL)
%RE %RSD Measured 
value (pg/mL)
%RE %RSD
200 (LLOQ) 230.08 15.04 1.35 178.99 −10.50 8.09 220.79 10.40 7.13
234.48 17.23 172.00 −14.00 192.30 −3.85
237.15 18.58 203.32 1.66 200.79 0.39
232.03 16.01 203.14 1.57 225.18 12.59
229.60 14.81 177.03 −11.48 224.60 12.30
%RSD interday=10.72
1,000 (QCL) 936.26 −6.37 3.91 864.77 −13.52 4.39 930.72 −6.93 5.74
979.20 −2.08 876.70 −12.33 1059.39 5.94
1028.53 2.85 881.20 −11.88 989.99 −1.00
1029.27 2.93 887.47 −11.25 1076.16 7.62
986.42 −1.36 963.35 −3.66 1006.12 0.61
%RSD interday=7.07
5,000 (QCM) 4929.81 −1.40 9.69 5279.90 5.60 3.09 5146.15 2.92 4.10
5449.11 8.98 5453.03 9.06 4838.69 −3.23
4422.43 −11.55 5034.94 0.70 5180.03 3.60
4579.13 −8.42 5115.57 2.31 5403.74 8.07
4317.36 −13.65 5259.97 5.20 5008.43 0.17
%RSD interday=7.09
7,500 (QCH) 733.41 −2.21 5.94 8189.70 9.20 3.87 7559.99 0.80 4.00
7077.48 −5.63 7503.51 0.05 7991.97 6.56
7969.32 6.26 7691.52 2.55 7984.06 6.45
7651.44 2.02 7443.02 −0.76 8057.02 7.43
8192.68 9.24 7596.15 1.28 7359.58 −1.87
%RSD interday=4.42
LLOQ: Lower limit of quantification, QC: Quality control, QCL: Quality control low, QCM: Quality control medium, QCH: Quality control high, RSD: Relative standard 
deviation, RE: Relative error
Fig. 3: Representative multiple reaction monitoring 
chromatograms of an extracted 200 pg/mL lower limit of 
quantification plasma sample
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Selectivity test
The selectivity test was performed to measure the ability of the 
analytical method to differentiate and quantitatively measure an 
analyte in a biological matrix. The selectivity was measured using 
the %RSD and %RE. According to the study results, the %RSD of the 
clopidogrel was 4.63%, with %RE values of 5.35-18.70%, which still 
met the requirements. In addition, the chromatogram from the plasma 
blank did not show any interference from the endogenous compounds 
in the plasma samples obtained from the six individual donors, thus 
meeting the selectivity requirements (Figs. 3 and 4).
Carryover
This study was performed to measure whether the residues of the 
analyte and internal standard were carried over to the plasma blank after 
the injection of the highest concentration (upper limit of quantitation 
or ULOQ). The carryover result from the clopidogrel retention time 
was not more than 12.76%, with an average of 5.835%. As the internal 
standard, the carryover result from the irbesartan retention time was 
not more than 0.828%, with an average of 0.733%.
Dilution integrity
This test was performed to assess the dilution process used for the 
analysis, which did not affect the accuracy and precision of the results. 
In this study, the %RE values obtained from the intraday test for the 1:2 
dilution were 0.03-4.37%, with a %RSD of 1.86%; for the 1:4 dilution, 
the %RE values were −5.14-0.07%, with a %RSD of 1.99%. The %RE 
values obtained from the interday test for the one-half dilution were 
7.008-0.03%, with a %RSD of 2.15%; for the 1:4 dilution, the %RE 
values obtained were −6.95-7.81%, with a %RSD of 3.78%.
Stability test
The stability data showed that the clopidogrel and irbesartan were 
stable for at least 30 days in the acetonitrile stock solutions stored at 
−20°C, as concluded from the %RE values (−0.07%-1.34%). The results 
of the stability test of the analytes in the samples during storage for 24 
hrs using the autosampler were within the %RE range required (−5.9-
1.12%). The stability of the analytes in the plasma samples during 
storage at room temperature for 24 hrs was expressed by the %RE 
values (−8.66-9.24%). The %RE values obtained from the long-term 
stability study were −3.16-9.24%. This proved that the analytes were 
stable in the plasma samples during the 10 days, they were stored in 
the freezer at −20°C. Moreover, the analytes were proven to be stable in 
the plasma samples after three freeze-thaw cycles, as demonstrated by 
the %RE values obtained (−8.79-9.24%).
Matrix effect
According to the experiment performed, the matrix factor 
value obtained for the QCL was 101.376%, meaning that at this 
concentration, there was ions enhancement, although not significantly, 
the value was near 100% [10-13]. The matrix factor value obtained 
in the high concentration was 85.053%, meaning that there was ions 
suppression [14,15]. The internal standard matrix factor value was 
99.463%, meaning that there was a slight decrease in the ions. However, 
the percentage of RSD values of the matrix factor for the analyte and 
internal standard still met the criterion (<15%).
CONCLUSION
The analytical method developed in this research can be used to analyze 
the clopidogrel concentration in the plasma. It met the validation 
requirements according to 2011 EMA Guideline on Bioanalytical 
Method Validation with regard to the selectivity, accuracy, precision, 
carryover, linearity, matrix effect, dilution integrity, and stability.
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